Oncology Product Portfolio
Oncology-only · EU-GMP / WHO-GMP sourcing · NAFDAC & PCN aligned
Platinum-Based Chemotherapy
Carboplatin, cisplatin and oxaliplatin for first-line cancer treatment.
Taxanes
Paclitaxel and docetaxel used across common solid tumours.
Antimetabolites & Cytotoxic Agents
Core cytotoxic medicines used in standard chemotherapy regimens.
Supportive Oncology Medicines
Supportive therapies used alongside chemotherapy treatment.
Oral & Endocrine Therapies
Oral and hormonal therapies for breast and prostate cancer.
Targeted & Specialty Oncology Pipeline
Selected targeted oncology medicines under evaluation.
Built Around Real Oncology Practice
Our portfolio is designed around regimens that Nigerian oncologists use every day. We focus on molecules that are widely used, clinically meaningful and realistically sustainable within local budgets.
Backbone chemotherapy agents for solid tumours
Oral therapies and endocrine agents
Supportive medicines that protect treatment continuity
Products sourced from EU-GMP / WHO-GMP manufacturers
NAFDAC-registered or in process, in line with regulations
Example Molecules
Our range includes widely used oncology molecules such as carboplatin, oxaliplatin, cisplatin, paclitaxel, docetaxel, capecitabine, tamoxifen, aromatase inhibitors and selected supportive agents like filgrastim.
Availability is subject to NAFDAC registration status and stock levels. For an up-to-date product list, please contact our team.
Core Chemotherapy Injectables
Our injectable portfolio focuses on widely used backbone regimens in solid tumours. Example molecules include:
-
Carboplatin
-
Oxaliplatin
-
Cisplatin
-
Paclitaxel
-
Docetaxel
This list is illustrative only and may change over time. Please contact us for a current list and strengths available.
Need a Detailed Product List?
Share your oncology formulary or specific molecules of interest, and we’ll confirm which products we can support today and which are in our future pipeline.
Information on this page is intended for healthcare professionals and business partners only. It does not replace clinical guidelines, national protocols or the judgement of treating physicians. Product availability is subject to NAFDAC registration status and stock levels.